Crestt Tablet 10/20 mg (Ezetimibe, Rosuvastatin)

Adult dose

This medication is administered once daily regardless of meal timing. For primary hypercholesterolemia, an initial dose of 10/5 mg is recommended, and can be adjusted between 10/5 mg and 10/20 mg depending on therapeutic response. After initiation of treatment or dose adjustment, blood lipid levels should be checked at intervals of at least 4 weeks to adjust the dosage.

This medication carries a risk of rhabdomyolysis, which can cause muscle tissue damage leading to acute kidney failure. Caution should be taken, and temporary discontinuation may be necessary, especially in patients with severe symptoms of myopathy or risk factors such as severe infections, hypotension, major surgery, trauma, metabolic and electrolyte disorders. Patients with a history of allergic reactions to this medication’s active ingredients or components, patients with active liver disease, those with muscle disorders, patients using specific immunosuppressants, patients with severe renal impairment, pregnant or potentially pregnant women, and breastfeeding mothers should not take this medication. Moderate renal impairment, hypothyroidism, a history of genetic muscle disease, a history of muscle toxicity from other statins or fibrate medications, alcohol dependence, and Asian patients are among those who should also take this medication with caution. This medication contains lactose and should not be administered to patients with lactose intolerance. Patients with a history of alcoholism or liver disease should be carefully monitored for potential liver function deterioration. It is not recommended for patients with severe liver dysfunction. If muscle-related adverse effects such as muscle pain, myopathy, or rhabdomyolysis occur, patients should immediately inform their physician and undergo examination, and in severe cases, discontinuation of the medication should be considered. Liver function tests should be conducted at baseline, and if liver enzyme levels rise abnormally during treatment, dosage adjustments or discontinuation of the medication should be evaluated. Blood sugar levels may increase during treatment with this medication, but it is considered that the cardiovascular risk reduction benefit outweighs the risk of increased blood sugar levels. There may be interactions when taking this medication with other drugs, especially when used with anticoagulants, fibrate class drugs, certain antibiotics, and antifungals, so caution is required in these combinations. Pregnant or breastfeeding women should not take this medication due to risks to the fetus and infant, and women of childbearing potential should employ appropriate contraception while on this medication. Special caution is required when administering to children and the elderly, and safety for children has not been established. In cases of overdose, treatment should be symptomatic, and liver and muscle enzyme tests should be conducted appropriately. This medication should be kept out of reach of children and should not be transferred to another container.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes, trouble breathing, asthma attack, respiratory issues accompanied by cough+fever, yellowing of skin or eyes (jaundice), extreme lethargy, sudden and severe headache, thunderclap headache, seizure, confusion, visual disturbances, paralysis, urinary issues.

Mild side effects

• Pharyngitis
• dyspepsia
• headache
• dry mouth
• elevated liver enzymes
• myalgia
• edema
• pruritus
• dizziness
• drowsiness

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain storage temperatures between 1°C and 30°C. Proper storage can ensure the medication's effectiveness.

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3), 30 tablets/bottle, 100 tablets/bottle